NY-PRODAPT
22.11.2022 13:01:40 CET | Business Wire | Press release
Prodapt, a leading global consulting, technology & managed services provider with a singular focus on the Connectedness industry, has been named a recipient of the Salesforce Partner Innovation Award in the "Communications" category. The prestigious award recognizes Prodapt’s contributions to Salesforce-driven digital transformation programs and the development of specific solution accelerators for the communications industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221122005351/en/
Prodapt is the winner of the Salesforce Partner Innovation Award 2022 in the Communications category (Graphic: Business Wire)
Each year, the Salesforce Partner Innovation Awards recognize the significant contributions Salesforce partners have made across clouds, industries, and the broader partner program – including consulting firms, digital agencies, resellers, and ISV partners. IDC, a global provider of market intelligence and advisory services for the IT, telecommunications, and consumer technology markets, facilitated and judged the nominations.
Prodapt tendered its nomination for the CRM transformation of Fiber Network Delivery to support multiple new operating models. The award affirms Prodapt’s continuous efforts in delivering value to its global clients by accelerating its transformation initiatives.
“In today’s world of fierce competition, customer volatility, and economic uncertainty, excellence in innovation has become a critical differentiator. The Partner Innovation Award in the Communications space signifies our track record in facilitating end-to-end CRM transformations that deliver business outcomes, leveraging our deep industry expertise.” – Smita Katariya | Vice President, Prodapt.
“Salesforce Partner Innovation Award winners, such as Prodapt, help customers grow faster and reach further in this new digital economy,” said Tyler Prince, Executive Vice President, Alliances & Channels at Salesforce. “Salesforce partners are integral to enabling digital transformation and driving customer success.”
For further details on Salesforce Partner Innovation Awards, visit: https://www.salesforce.com/news/stories/salesforce-2022-partner-innovation-award-winners/
Salesforce and others are among the trademarks of Salesforce.com, Inc.
About Prodapt
Prodapt is the largest and fastest-growing EXCLUSIVE player in the Connectedness space, serving global firms that ultimately seek to connect people.
Prodapt prides itself on long-tenured client relationships and has always been considered a valuable partner by clients. Prodapt serves global leaders across telecom, internet, media, and entertainment, such as Google, Facebook, Amazon, Microsoft, AT&T, Verizon, Liberty Latin America, Lumen, Adtran, Vodafone, Liberty Global, Windstream, Virgin Media, Rogers, KPN, BT, and Deutsche Telekom, among many others.
Prodapt is A Great Place to Work certified company with a workforce of over 5000 spread across 32 countries spanning the Americas, Europe, Africa, and Asia. Prodapt is part of the 120-year-old business conglomerate, The Jhaver Group, which employs over 22,000 people across 64+ locations globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005351/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release
Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
